540501-23-3

Usage

Molecular structure

The compound has a complex structure consisting of a pyrrolidine ring, a carboxylic acid group, a 1,1-dimethylethyl ester group, a dimethylsilyl group, and a methylene group.

Pyrrolidinecarboxylic acid

The core structure of the compound is a pyrrolidine ring, which is a five-membered nitrogen-containing heterocyclic ring, and a carboxylic acid group (-COOH) attached to it.

1,1-Dimethylethyl ester

The compound is esterified with a 1,1-dimethylethyl group, which is an ester functional group formed by the reaction of the carboxylic acid group with an alcohol.

Dimethylsilyl group

The compound contains a dimethylsilyl group (-Si(CH3)2), which is a silicon-based group with two methyl groups attached to it. This group can influence the compound's reactivity and stability.

Methylene group

The compound also has a methylene group (-CH2-), which is a carbon-hydrogen group that can act as a linker between different parts of the molecule.

Upstream product

• 1779-49-3 Methyltriphenylphosphonium bromide 
• 220993-22-6 (S)-tert-butyl 2-((tert-butyldimethylsilyloxy)methyl)-4-oxopyrrolidine-1-carboxylate 

Downstream Products

• 364750-80-1 (2S,4R)-1-[(tert-butoxy)carbonyl]-4-methylpyrrolidine-2-carboxylic acid 

Relevant academic research and scientific papers

PYRROLOBENZODIAZEPINE DIMER PRECURSOR AND LIGAND-LINKER CONJUGATE COMPOUND THEREOF

The present invention relates to a pyrrolobenzodiazepine dimer prodrug and a ligand-linker conjugate compound thereof, a composition containing these, and therapeutic use thereof particularly as an anticancer drug. The stability of the compounds themselves and the stability thereof in plasma are excellent and the compounds are advantageous in terms of manifestation of toxicity, and thus the compounds are industrially useful in that it is possible to target proliferative diseases such as cancer, to perform a specific treatment, to maximize the drug efficacy, and to minimize the occurrence of side effects.

NOVEL ANTIBACTERIAL COMPOUNDS

The invention relates to novel chimeric antibiotics of formula (I) Wherein R1 is CH2NHCOR5, heteroarylmethyl, heteroaryloxymethyl or heteroarylaminomethyl; R2 is H, OH, OSO3H, OPO3H2, OCH2OPO3H2, OCOCH2CH2COOH, OCOR6; R3 is H or halogen; R4 is (C1-C3)alkyl, (C1-C3)haloalkyl or cycloalkyl; R5 is alkyl or haloalkyl; and R6 is the residue of a naturally occurring amino acid or of dimethylaminoglycine. These chimeric compounds are useful in the manufacture of medicaments for the treatment of infections (e.g. bacterial infections).

Asymmetric hydrogenations for the synthesis of boc-protected 4-alkylprolinols and prolines

The utility of 4-substituted prolinols and their corresponding prolines in peptides, peptidomimetics, and natural products has motivated researchers to find new and efficient routes for their preparation. Herein, we report a general approach to the synthesis of Boc-protected 4-alkylprolinols and prolines via a divergent asymmetric hydrogenation strategy. Intermediate exocyclic olefins were prepared by Wittig-type reactions with ketone 6 and subjected to hydroxyl and sterically directed reductions. The Crabtree catalyst (Ir[COD] PyPCy3PF6) proved to be highly effective in diastereoselective hydrogenations to give trans- substituted pyrrolidines (9). Good facial selectivities were also observed in heterogeneous hydrogenations with Raney-nickel to obtain cis-substituted pyrrolidines (11). Employing this strategy, we describe the synthesis of novel prolinol and proline-based building blocks for incorporation into biologically relevant peptidomimetics.